A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?
Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including recurrence, metastasis, and mortality.
Salvage cryoablation following local recurrence post radiation may be a safe way to avoid or delay initiation of hormone deprivation therapy.
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
Abiraterone has become the first-choice treatment for men with metastatic prostate cancer.
Chemotherapy is the best option for the initial management of metastatic prostate cancer.
An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non–muscle-invasive urothelial cancer.
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.